

fragments thereof capable of inhibiting the binding of cytokines IL-3, GM-CSF and IL-5 to the common receptor  $\beta_c$ , wherein the monoclonal antibody or fragments thereof binds to both the B'-C' loop and the F'-G' of domain 4 of the  $\beta_c$  subunit.


37. (NEW) A method of inhibiting the IL-5, IL-3 or GM-CSF mediated leukaemic cell proliferation as in claim 32 wherein the monoclonal antibody or fragments thereof are BION-1 or fragments thereof.
38. (NEW) A method of inhibiting IL-5, IL-3 or GM-CSF mediated eosinophil activation, eosinophil production or eosinophil survival, by contacting the eosinophils with monoclonal antibody or fragments thereof capable of inhibiting the binding of cytokines IL-3, GM-CSF and IL-5 to the common receptor  $\beta_c$ , wherein the monoclonal antibody or fragments thereof binds to both the B'-C' loop and the F'-G' of domain 4 of the  $\beta_c$  subunit.
39. (NEW) A method of inhibiting IL-5, IL-3 or GM-CSF mediated eosinophil activation, eosinophil production or eosinophil survival, as in claim 38 wherein the monoclonal antibody or fragments thereof are BION-1 or fragments thereof.

#### **REMARKS**

Favorable consideration of this application as presently amended is respectfully requested.

In view of the foregoing, it is respectfully submitted that this application is in condition for allowance, and favorable action is respectfully solicited.

Respectfully submitted,



Henry D. Coleman  
Reg. No. 32,559

Coleman Sudol Sapone, P.C.  
714 Colorado Avenue  
Bridgeport, CT 06605-1601  
(203) 366-3560

February 9, 2004